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Hereditary angioedema (HAE) is characterized clinically by recurrent acute skin swelling, abdominal pain, and potentially
life-threatening laryngeal edema. Three forms of HAE have been described. The classic forms, HAE types I and II, occur
as a consequence of mutations in the C1-inhibitor gene. In contrast to HAE types I and II, HAE type III has been observed
exclusively in women, where it appears to be correlated with conditions of high estrogen levels—for example, pregnancy
or the use of oral contraceptives. A recent report proposed two missense mutations (c.1032CrA and c.1032CrG) in F12,
the gene encoding human coagulation factor XII (FXII, or Hageman factor) as a possible cause of HAE type III. Here, we
report the occurrence of the c.1032CrA (p.Thr328Lys) mutation in an HAE type III–affected family of French origin.
Investigation of the F12 gene in a large German family did not reveal a coding mutation. Haplotype analysis with use
of microsatellite markers is compatible with locus heterogeneity in HAE type III. To shed more light on the pathogenic
relevance of the HAE type III–associated p.Thr328Lys mutation, we compared FXII activity and plasma levels in patients
carrying the mutation with that of healthy control individuals. Our data strongly suggest that p.Thr328Lys is a gain-of-
function mutation that markedly increases FXII amidolytic activity but that does not alter FXII plasma levels.We conclude
that enhanced FXII enzymatic plasma activity in female mutation carriers leads to enhanced kinin production, which
results in angioedema. Transcription of F12 is positively regulated by estrogens, which may explain why only women
are affected with HAE type III. The results of our study represent an important step toward an understanding of the
molecular processes involved in HAE type III and provide diagnostic and possibly new therapeutic opportunities.
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Hereditary angioedema (HAE [MIM #106100]) is an auto-
somal dominant condition characterized clinically by re-
current attacks of facial, genital, or peripheral skin edema
without urticaria. The angioedema episodes are potentially
life threatening because of occasional attacks of laryngeal
and/or intra-abdominal swelling.1,2 The majority of HAE
cases are attributable to inadequate C1-inhibitor protein
function as a consequence of mutations in SERPING1, the
gene encoding C1 inhibitor.3,4 At the molecular level, two
clinically indistinguishable categories are recognized: HAE
type I, characterized by dramatically reduced levels of the
C1 inhibitor (e.g., as a consequence of SERPING1deletions),
and HAE type II, characterized by normal C1-inhibitor lev-
els but impaired protein function as a consequence of SERP-
ING1 missense mutations. HAE swelling is independent of
histamine release but is related to excessive generation of
vasoactive kinin peptide hormones, in particular bradyki-
nin, in affected tissues.2,5
We and others have recently described pedigrees of in-
dividuals exhibiting HAE who have normal C1-inhibitor
concentration and function.1,6,7 Patients from these pedi-
grees are exclusively women, and their episodes of angio-
edema are precipitated or worsened by high estrogen lev-
els (e.g. during pregnancy or treatment with oral contra-
ceptives). This new type of HAE has been termed “HAE
type III” (MIM %300268) or, more comprehensively, “es-
trogen-related HAE” or “estrogen-sensitive HAE.”6 Binkley
and Davis6 have excluded the possibility that mutations
at the C1-inhibitor locus are the genetic cause of HAE type
III and have suggested that a different locus must be re-
sponsible for this phenotype.
We have previously performed a genomewide linkage
study of four German families with HAE type III reported
by Bork et al.1 and have found evidence of the presence
of a disease-causing gene in chromosomal region 5q35.2-
q35.3 (authors’ unpublished data). For three of these fam-
ilies, Dewald and Bork8 recently reported a missense mu-
tation (c.1032CrA, which results in a p.Thr328Lys sub-
stitution) in F12, the gene for blood-coagulation factorXII
(FXII, or Hageman factor), which is located in this partic-
ular chromosomal region. The F12 gene can be considered
a strong candidate for HAE type III for two reasons: FXII
proteolytic activity is involved in generation of kinins,
which increase vascular leakage and trigger edema forma-
tion, and FXII expression and plasma levels are known to
be regulated by estrogens.9,10 These results suggest that
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Figure 1. Haplotype analysis with use of genetic markers at chromosomal region 5q35.2-q35.5 in a French family with HAE type III.
The presence of a C or an A in the second position of codon 328 of F12 (located between D5S2111 and D5S2030) is indicated by the
resulting amino acid (Thr or Lys). To avoid disclosure of carrier status of unaffected individuals, only affected individuals, obligate
carriers, and founder individuals are depicted. The putative disease-associated haplotype(s) is boxed. A missing genotype is indicated
by a hyphen (-). The presence of 328Lys is associated with a history of angioedema attacks.
mutated F12 could be the sought-after disease-causing
gene for HAE type III.
In the present study, we report additional genetic and
functional data that shed more light on themolecular basis
of HAE type III. We investigated the F12 locus in two new
families with HAE type III, one of French and the other of
German origin. Whereas the French family segregates a
c.1032CrA (p.Thr328Lys)mutationpreviously identiﬁedin
German families, thus supporting its potential pathogenic
relevance, no F12-codingmutation could be detected in the
German family. We performed haplotype analyses com-
patible with the presence of locus heterogeneity. The oc-
currence of the same mutation (c.1032CrA) in three
German families and one French family prompted us to
investigate whether this mutation had arisen indepen-
dently or whether it originates from a common founder.
Haplotype analyses with use of SNPs at the F12 locus pro-
vided evidence that the German and French families share
a common founder. Finally, we present comprehensive
functional data that demonstrate the pathogenic relevance
of the p.Thr328Lys missense mutation in FXII. Our data
strongly suggest that p.Thr328Lys in FXII is an activating
mutation that most probably causes angioedema through
a bradykinin-driven pathomechanism.
In a ﬁrst step, we investigated the F12 locus in two ex-
tended pedigrees with HAE type III, one from Germany,
which two of us had previously reported independently,1,7
and the other from France (ﬁg. 1). Before sequencing the
F12 gene, we genotyped microsatellite markers around the
F12 locus, at 5q35.2-q35.3, in all available familymembers
and performed haplotype analysis to conﬁrm linkage of
the disease to this locus.
In the French family, analysis of markers D5S2034,
D5S2111, and D5S2030 identiﬁed a putative disease-asso-
ciated haplotype that was present in all affected females
and obligate carriers (ﬁg. 1). We subsequently undertook
a systematic sequence analysis of the F12 coding region.
All 14 exons and exon-ﬂanking intronic regions were am-
pliﬁed by standard PCR in two affected women and in one
healthy spouse in both the French and German families.
PCR products were sequenced directly on an automated
ABI 3130 XL capillary sequencer (Applied Biosystems).
The obtained nucleotide sequences were compared be-
tween affected and unaffected individuals and with the
human F12 cDNA sequence (gi:9961354). We identiﬁed
only one sequence change affecting the primary structure
of the protein: a CrA change in position 1032 (c.1032CrA)
that resulted in a p.Thr328Lys substitution in the proline-
rich domain (ﬁg. 2). All affected women were carriers of
the p.Thr328Lys mutation. Six unaffected women from
the last generation also carried the mutation, as predicted
from the segregation of disease-associated haplotypes. The
mutation was not present in 1,000 control chromosomes.
Haplotype analysis in the German family (F10) was per-
formed using markers D5S2034, D5S2111, and D5S2030
as well as two additional markers (D5S498 and D5S408)
that had been genotyped in the course of a genome scan.
We could not identify a disease haplotype that was present
in all affected women (data not shown). Assignment of a
putative disease haplotype was possible only under the
assumption that one affected female represented a phe-
nocopy and that one unaffected female (an obligate car-
rier) was a nonpenetrant case. For another affected female,
limited marker information meant that it was not possible
to decide whether she had inherited the putative disease
haplotype.
The occurrence of the same mutation (c.1032CrA) in
a French family and in three German families described
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Figure 2. Thr328Lys mutation in factor XII in patients with HAE type III. a, Sequencing proﬁles showing part of exon 9 (nucleotide
positions 1027–1037, according to cDNA sequence gi:9961354) in an affected female (III:2) from the French family (left panel) and
in a control individual (right panel). b, Schematic picture of the primary structure of the factor XII protein, with known functionally
important domains indicated as boxes. Amino acid ranges covering functional domains are given below the primary structure. The
location of the Thr328Lys mutation in the proline-rich domain is indicated by an arrow.
elsewhere (F01, F02, and F05 in this study; designated
“family 005,” “family 004,” and “family 003” in the study
by Dewald and Bork8) is striking and raises the question
of whether independent mutational events have taken
place in these families or whether they share a common
founder. We addressed this question by performing hap-
lotype analysis with use of 10 SNPs and the c.1032CrA
mutation in F12 (ﬁg. 3). Our results are compatible with
the hypothesis that the p.Thr328Lys mutation in the one
French and the three German families can be traced to
a common founder. In a next step, we estimated the age
of the most recent common ancestor (MRCA) of the
c.1032CrA mutation-bearing chromosomes. The pres-
ence of signiﬁcant linkage disequilibrium (LD) ( , cal-d 1 0.1
culated according to the method of Bengtsson and Thomp-
son11) at four markers (D5S498, D5S2034, D5S2111, and
D5S408) as well as the availability of deﬁned map dis-
tances for each of them allowed the estimation of the
coalescence time. Age was ﬁrst estimated by two moment
methods,12,13 both of which are based on the “genetic
clock” equation, , which relates the time (inlnQpvg
generations [g]) since the MRCA of mutant chromosomes,
the frequency of recombination between the disease locus
and the marker (v), and the probability that a marker’s
allele on a disease chromosome is the ancestral one (Q).14
The sex-averaged v between each microsatellite and F12
gene was estimated on the basis of the physical distance
(in Mb) (National Center for Biotechnology Information
build 36.1; UCSCGenome BrowserMarch 2006 assembly).
The genetic distance:physical distance ratios (2.36:2.98
cM/Mb) were taken from the deCODE high-resolution
recombination map.15 An unbiased estimate of Q is the
proportion of observed haplotypes that are ancestral. The
genetic clock was set following the approach of Luria
and Delbru¨ck,16 which takes into account the population
growth rate (d). Accordingly, the estimated age was cor-
rected by adding to the g value.17 Underg p(1/d) ln (v/d)0
the second moment method,13 it was possible to correct
the decay of LD over generations for the mutation rate
( for dinucleotide repeats18) at marker loci. LDmp 0.00056
data were also used to infer the MRCA age, with use of
the Bayesian Markov chain–Monte Carlo method of Ran-
nala and Reeve,19 implemented in the DMLE program,
version 2.14 (DMLEDiseaseMapping Using LinkageDis-
equilibrium Web site). The posterior probability distribu-
tion (P) of the c.1032CrA mutation age was inferred as-
suming a proportion of mutation-bearing chromosomes
in our sample that conservatively represents the expected
allele frequency and allows us to obtain good convergence
of P. The population growth parameter ( ) rests ondp 0.08
the demographic history of Western Europe.
The mean ( SD) overall age estimate for the c.1032CrA
mutation is (95% CI with use31.8 18.9 g 10.4–52.3 g)
of the ﬁrst algorithm12 and is (95% CI29.1 18.3 g
) with use of the iterative method of Reich and8.3–49.8 g
Goldstein.13
Because simple parametric age estimators obtained an-
alytically from the genetic-clock equation suffer from the
uncertainty about the intra-allelic genealogy, LDdatawere
reanalyzed in a Bayesian perspective with use of a Markov
chain–Monte Carlo method.19 Under the assumption that
, the Bayesian inference provided an estimationdp 0.08
of (95% CI ), an age similar to the one34.2 g 15.1–92.7 g
obtained by the moment methods. However, the upper
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Figure 3. Haplotype analysis in representative parents-offspring triads from three German families (F01, F02, and F05) and one French
family, showing the p.Thr328Lys mutation, with use of 10 SNPs covering the complete genomic region of the F12 gene and the disease-
causing mutation (c.1032CrA). SNPs without an “rs” number were identiﬁed as informative markers by sequencing analysis of F12 in
the families (ﬂanking sequences and assay conditions for the SNPs are available on request). Our results show that the disease-causing
mutation is located on the same haplotype (red) in all four families segregating the Thr328Lys mutation, which is compatible with the
hypothesis that the mutation goes back to a common founder.
limit of the CI is higher than the corresponding conﬁ-
dence limits resulting from parametric analysis of LD de-
cay over generations.
Under the assumption that years, our resultsgp 25–30
date the MRCA bearing the c.1032CrA mutation to the
11th century (minimum 95% CI 720–1510 A.D.; maxi-
mum 95% CI 820 B.C.–1750 A.D.).
In the absence of studies demonstrating a functional
effect, discussions regarding the pathogenic effect of mis-
sense mutations are always hypothetical. We therefore
aimed to investigate the functional consequences of the
p.Thr328Lys mutation in FXII. We determined FXII plasma
levels in patients, using an Dade Behring automated Beh-
ring Coagulation System and Dade Behring reagents, ac-
cording to the manufacturer’s instructions. FXII plasma
concentrations in patients with HAE type III were similar
to those in healthy controls ( vs. ;89%15% 97% 12%
two-tailed Mann-Whitney test: P is not signiﬁcant; np
) and within the normal range (70%–150% [10 100%p
mg/ml]). Using the chromogenic substrate S-2302 (D-30
Pro-Phe-Arg-p-nitroanilide, 6 mM, 20-min reaction time),
which is speciﬁcally hydrolyzed by active FXII (FXIIa), we
compared amidolytic activity in plasma from patients
with HAE type III with that from healthy individuals.Mu-
tation p.Thr328Lys largely increases FXII amidolytic ac-
tivity (more than fourfold), as compared with controls
( vs. ; ; ) (ﬁg. 4a). In-0.73 0.34 0.15 0.01 P ! .005 np 10
creased enzymatic activity in patient plasma was com-
pletely blocked by FXIIa inhibitor H-D-Pro-Phe-Arg-chlo-
romethylketone (2 mM), which speciﬁcally inhibits FXII
activation in human plasma (ﬁg. 4b).20 Our data strongly
suggest that Thr328Lys is a gain-of-functionmutation that
results in increased FXII amidolytic activity but that does
not alter FXII plasma levels.
In patient IV:11 of family F10, who shows neither the
Thr328Lys mutation nor any other coding F12 gene mu-
tation, both FXII amidolytic activity and plasma levelwere
indistinguishable from those of healthy control patients
(ﬁg. 4b).
HAE types I and II are associated with mutations of the
C1-inhibitor gene (SERPING1), located in chromosomal re-
gion 11q12-q13.1. It has recently been suggested that a
c.1032CrA substitution in the F12 gene on 5q35.3, lead-
ing to a threoninerlysine amino acid change in the pro-
line-rich domain of factor XII, caused HAE type III.8 The
identiﬁcation of the same mutation in a French family
further supports this notion. In fact, there are several ar-
guments in favor of the hypothesis that factor XII bearing
Lys328 is a molecular cause of HAE type III: on the ba-
sis of the striking clinical similarity between classic HAE
(types I and II) and HAE type III, it can be hypothesized
that the three HAE types are caused by similar patho-
physiological mechanisms. In this respect, F12 is a strong
candidate gene, since it acts on the same biochemical
pathway as does the C1 inhibitor—namely, the produc-
tion of bradykinin, which is a strong inducer of vasodi-
lation and increased vasopermeability. An overproduction
of kinins, especially bradykinin, is thought to be respon-
sible for the localized swelling reactionsobserved inHAE.2,3,5
Factor XII is a serine protease that circulates in the blood
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Figure 4. Analysis of FXII activity in plasma from patients with
HAE type III. a, Relative FXII amidolytic activity in plasma from
HAE type III and healthy individuals (control), determined using
the FXIIa-speciﬁc chromogenic substrate S-2303. Substrate turn-
over was measured photometrically via absorbance at a 405-nm
wavelength. Data are presented in box-and-whisker plots showing
the median (dark line in the box), 25th–75th percentiles (box),
and 5th–95th percentiles (whiskers). b, Time course of S-2303
turnover in plasma of a representative patient with HAE type III
(“French fam, IV:01”) from the French family, in the absence or
presence of the FXIIa inhibitor PCK (2 mM) and in a patient with
HAE type III (“F10, IV:11”) from German family F10. For compar-
ison, FXII substrate cleavage in a plasma sample from a healthy
control is plotted. Whereas FXII amidolytic activity is markedly
increased because of the p.Thr328Lys mutation in the French pa-
tient, FXII activity is normal in the German patient.
as a zymogen. FXII zymogen is activated by contact with
negatively charged surfaces, which gives rise to the name
of the FXII-driven cascade as a “contact activation sys-
tem.” In vitro, such negatively charged surfaces may be
phospholipids released from activated platelets and dam-
aged cells. In vivo, it has been demonstrated that FXII
activation is linked to platelet activation.21 FXIIa cleaves
plasma prekallikrein to form plasma kallikrein, which, in
turn, generates bradykinin from high-molecular-weight
kininogen.22 Under physiological conditions, the C1 in-
hibitor controls this cascade by inactivating FXIIa and
plasma kallikrein. In HAE types I and II, C1-inhibitor de-
ﬁciency results in an uncontrolled proteolytic activity of
FXII and plasma kallikrein as well as consecutive excessive
bradykinin formation. Our data strongly suggest that the
HAE type III–associated p.Thr328Lys mutation in FXII
might also cause angioedema through a bradykinin-driven
pathomechanism. However, in contrast to HAE types I and
II, in which excessive protease activity is due to deﬁciency
of the endogenous FXII inhibitor, Thr328Lys is a gain-
of-function mutation that increases enzymatic activity of
FXII. Pathological FXII activity may trigger excessive bra-
dykinin generation, which results in an increase of endo-
thelial permeability and vascular leakage.9 Although the
in-depth structural consequences of p.Thr328Lys remain
to be identiﬁed, the location of the mutation in the pro-
line-rich domain (aa positions 296–349 [ﬁg. 2])—one of
three domains involved in the binding of factor XII to
negatively charged surfaces23—strongly suggests that the
substitution of a neutral threonine residue by a positively
charged lysine in this domain may enhance activation of
FXII as a consequence of more-effective binding to neg-
atively charged surfaces.24
Further support for an involvement of FXII in HAE type
III is derived from the fact that the expression of FXII is
increased by estrogens via estrogen-responsive elements
in the promoter region.10 This may explain why only wo-
men are affected in our HAE type III–affected families and
why there is a correlation between episodes of angioedema
and periods of elevated estrogen-levels—for example, dur-
ing pregnancy or treatment with oral contraceptives or
estrogen-replacement therapy. The functional properties
and estrogen-dependent expression of FXII promptedBink-
ley and Davis6 to search for possible gain-of-functionmu-
tations in estrogen-responsive elements in the promoter
region of F12 in a large HAE type III kindred from southern
Italy. They did not identify mutations and speculated that
other putative estrogen-responsive sequences outside the
immediate 5′-ﬂanking region might contain a mutation.
It would certainly be worthwhile to examine this family
for the presence of coding gain-of-function mutations,
such as p.Thr328Lys. It is also noteworthy that we did not
observe altered FXII plasma levels in patients with HAE
type III who have the p.Thr328Lys mutation, in compar-
ison with control individuals. This observation shows that
there is no undetected mutation in the regulatory region
of F12 that is in complete LD with p.Thr328Lys, which
could be the underlyingmutation for disease development
through an inﬂuence on expression levels of FXII.
Interestingly, it has recently been demonstrated that
FXII is essential for pathological thrombus formation in
mouse models of ischemic stroke.20 Given the fact that
FXII activity will trigger thrombosis in humans via similar
pathways, it will be interesting to correlate FXII-driven
edema formation and risk of venous and/or arterial throm-
bosis in patients suffering from HAE type III. Furthermore,
since PCK efﬁciently interferes with pathological FXII ac-
tivation in postischemic vessels,20 this substance might be
a promising candidate for treatment of the acute swelling
attacks suffered by patients with HAE type III.
Surprisingly, we did not ﬁnd a mutation in the coding
region of F12 in German family F10. Haplotype analysis
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with microsatellite markers including the F12 gene were
compatible with the presence of a disease-causing muta-
tion only at this locus, under the assumption that one of
the affected women represents a phenocopy and that an-
other unaffected woman is a nonpenetrant carrier. Func-
tional studies in one patient showed normal FXII amido-
lytic activity and normal FXII plasma levels. These ﬁnd-
ings suggest that a so-far-unknown gene locus may be re-
sponsible for the HAE type III phenotype in this family.
Promising candidate genes include those that encode pro-
teins involved in FXII activation, FXII-driven bradykinin
signaling, or downstream effectors. Future studies will aim
to identify the disease-causing mutation in this and other
known families with HAE type III.
Interestingly, individual families with HAE and normal
C1-inhibitor concentration and function have been re-
ported in which males are also affected with the disease.25–
27 Whether the disease affecting these families can be clas-
siﬁed as HAE type III—and, consequently, whether it would
be preferable to describe the observed sex effect as occur-
ring “predominantly in females” rather than “exclusively
in females”—has been discussed.27 Alternatively, theremay
be at least two different forms of HAE with a normal C1
inhibitor, one limited to females (HAE type III) and the
other occurring in both sexes.27 The investigation of F12
in families with affected males will allow this question to
be addressed at the molecular level.
Striking clinical variability is observed among carriers
of the p.Thr328Lys mutation. Environmental factors, such
as exposure to triggering factors, as well as additional ge-
netic factors may account for this variability. Clearly, ge-
netic variants that inﬂuence factor XII levels will be prom-
ising candidates in the search for the factors underlying
clinical expression of the p.Thr328Lys mutation.
In conclusion, the results of our study provide impor-
tant insights into the molecular causes of HAE type III and
have important implications for the diagnosis of this po-
tentially life-threatening condition and possibly also for
the development of new therapies. Families carrying the
p.Thr328Lys mutation should receive immediate beneﬁt
from our results. Predictive testing in presymptomatic fe-
males will help prepare carriers for the recognition and
treatment of potential episodes of angioedema and may
inﬂuence individual decisions to avoid conditions of high
estrogen levels—for example, the use of oral contraceptives.
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